vTv Therapeutics (VTVT) Competitors

vTv Therapeutics logo
$17.29 -0.40 (-2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$17.06 -0.23 (-1.33%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VTVT vs. SPRY, TTRX, CGC, BIOA, and AMRN

Should you buy vTv Therapeutics stock or one of its competitors? vTv Therapeutics's main competitors and comparable companies include ARS Pharmaceuticals (SPRY), Turn Therapeutics (TTRX), Canopy Growth (CGC), BioAge Labs (BIOA), and Amarin (AMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does vTv Therapeutics compare to ARS Pharmaceuticals?

vTv Therapeutics (NASDAQ:VTVT) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, vTv Therapeutics and vTv Therapeutics both had 1 articles in the media. vTv Therapeutics' average media sentiment score of 1.09 beat ARS Pharmaceuticals' score of 0.91 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ARS Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

vTv Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -163.64%. vTv Therapeutics' return on equity of -10.15% beat ARS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A -10.15% -8.65%
ARS Pharmaceuticals -163.64%-453.93%-71.62%

vTv Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M67.97-$26.97M-$0.92N/A
ARS Pharmaceuticals$84.28M4.35-$171.30M-$2.02N/A

vTv Therapeutics presently has a consensus target price of $55.83, suggesting a potential upside of 222.92%. ARS Pharmaceuticals has a consensus target price of $23.33, suggesting a potential upside of 539.27%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
ARS Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

vTv Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

vTv Therapeutics beats ARS Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does vTv Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

17.5% of vTv Therapeutics shares are held by institutional investors. 55.9% of Turn Therapeutics shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Turn Therapeutics has higher earnings, but lower revenue than vTv Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A
vTv Therapeutics$1.02M67.97-$26.97M-$0.92N/A

In the previous week, Turn Therapeutics and Turn Therapeutics both had 1 articles in the media. vTv Therapeutics' average media sentiment score of 1.09 beat Turn Therapeutics' score of 0.89 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Turn Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
vTv Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Turn Therapeutics currently has a consensus target price of $9.00, indicating a potential upside of 5.26%. vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 222.92%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

vTv Therapeutics' return on equity of -10.15% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A -261.87% -70.18%
vTv Therapeutics N/A -10.15%-8.65%

Summary

vTv Therapeutics beats Turn Therapeutics on 8 of the 12 factors compared between the two stocks.

How does vTv Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Canopy Growth has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 0.4% of Canopy Growth shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

vTv Therapeutics has lower revenue, but higher earnings than Canopy Growth. vTv Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$251.01M0.90-$190.29M-$0.51N/A
vTv Therapeutics$1.02M67.97-$26.97M-$0.92N/A

vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 222.92%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

In the previous week, Canopy Growth and Canopy Growth both had 1 articles in the media. Canopy Growth's average media sentiment score of 1.31 beat vTv Therapeutics' score of 1.09 indicating that Canopy Growth is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Canopy Growth
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
vTv Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

vTv Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -73.03%. vTv Therapeutics' return on equity of -10.15% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Canopy Growth-73.03% -28.21% -17.97%
vTv Therapeutics N/A -10.15%-8.65%

Summary

vTv Therapeutics beats Canopy Growth on 11 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to BioAge Labs?

vTv Therapeutics (NASDAQ:VTVT) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

vTv Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -1,253.60%. vTv Therapeutics' return on equity of -10.15% beat BioAge Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A -10.15% -8.65%
BioAge Labs -1,253.60%-31.42%-29.59%

vTv Therapeutics presently has a consensus target price of $55.83, indicating a potential upside of 222.92%. BioAge Labs has a consensus target price of $33.00, indicating a potential upside of 547.06%. Given BioAge Labs' higher probable upside, analysts clearly believe BioAge Labs is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

17.5% of vTv Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 17.6% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

vTv Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

In the previous week, BioAge Labs had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for BioAge Labs and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.09 beat BioAge Labs' score of 0.45 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

vTv Therapeutics has higher earnings, but lower revenue than BioAge Labs. vTv Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M67.97-$26.97M-$0.92N/A
BioAge Labs$8.99M26.07-$80.61M-$2.55N/A

Summary

vTv Therapeutics beats BioAge Labs on 10 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Amarin?

vTv Therapeutics (NASDAQ:VTVT) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Amarin had 3 more articles in the media than vTv Therapeutics. MarketBeat recorded 4 mentions for Amarin and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.09 beat Amarin's score of 0.67 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amarin
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

vTv Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -10.87%. Amarin's return on equity of -0.52% beat vTv Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A -10.15% -8.65%
Amarin -10.87%-0.52%-0.36%

vTv Therapeutics has higher earnings, but lower revenue than Amarin. vTv Therapeutics is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M67.97-$26.97M-$0.92N/A
Amarin$213.65M1.11-$38.80M-$0.96N/A

vTv Therapeutics presently has a consensus target price of $55.83, suggesting a potential upside of 222.92%. Amarin has a consensus target price of $13.00, suggesting a potential upside of 15.35%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe vTv Therapeutics is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Amarin
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33

Summary

vTv Therapeutics beats Amarin on 10 of the 17 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTVT vs. The Competition

MetricvTv TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$70.96M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-18.7929.4034.1729.86
Price / Sales67.977.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book1.005.114.373.66
Net Income-$26.97M$2.88B$3.52B$392.27M
7 Day Performance-17.67%-4.10%-5.47%-4.73%
1 Month Performance-34.85%-5.08%-4.57%-7.14%
1 Year Performance-42.65%-7.47%-1.79%-7.51%

vTv Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTVT
vTv Therapeutics
2.924 of 5 stars
$17.29
-2.3%
$55.83
+222.9%
-42.6%$70.96M$1.02MN/A26
SPRY
ARS Pharmaceuticals
2.5863 of 5 stars
$3.57
+13.3%
$23.33
+553.6%
-56.3%$316.66M$84.28MN/A200
TTRX
Turn Therapeutics
1.5412 of 5 stars
$9.92
+1.3%
$9.00
-9.3%
+113.8%$298.92MN/AN/A2
CGC
Canopy Growth
1.1741 of 5 stars
$0.59
-4.9%
N/A-48.8%$279.82M$251.01MN/A1,128
BIOA
BioAge Labs
2.6847 of 5 stars
$5.78
+1.6%
$33.00
+470.9%
-33.1%$261.50M$8.99MN/A62

Related Companies and Tools


This page (NASDAQ:VTVT) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners